Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Lloyd M. Garrick"'
Publikováno v:
Beilstein Journal of Organic Chemistry, Vol 8, Iss 1, Pp 461-471 (2012)
Various arylsulfur pentafluorides, ArSF5, have long been desired in both academic and industrial areas, and ArSF5 compounds have attracted considerable interest in many areas such as medicines, agrochemicals, and other new materials, since the highly
Externí odkaz:
https://doaj.org/article/2f6cb6bce5124c93a5a6a6afd2c7b98d
Autor:
Charles William Mann, Lloyd M. Garrick, Matthew D. Vera, Linda Shanno, Jeffrey C. Pelletier, John F. Rogers, Diane B. Hauze, Jay E. Wrobel, Daniel M. Green, Irene Feingold, Murty Chengalvala, John F. Mehlmann, Joseph T. Lundquist, Joshua E. Cottom
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 20:2512-2515
Antagonism of the gonadotropin releasing hormone (GnRH) receptor has resulted in positive clinical results in reproductive tissue disorders such as endometriosis and prostate cancer. Following the recent discovery of orally active GnRH antagonists ba
Autor:
Lloyd M. Garrick, John F. Mehlmann, Diane B. Hauze, Joshua E. Cottom, Daniel M. Green, Jeffrey C. Pelletier, Murty Chengalvala, Irene Feingold, Joseph T. Lundquist, John F. Rogers, Charles William Mann, Linda Shanno, Jay E. Wrobel, Christine Huselton, Wenling Kao, Kees Kenneth L
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 19:1986-1990
A previous report described the serum LH suppression pharmacology of the 2-phenyl-4-piperazinyl-benzimidazole N-ethyluracil GnRH receptor antagonist 1 following oral administration in rats. A series of small heterocycles were appended to the 2-(4-ter
Autor:
Murty V. Chengalvala, Linda Shanno, Charles William Mann, Josh Cottom, Diane B. Hauze, Jay E. Wrobel, Irene Feingold, Jeffrey C. Pelletier, Gregory S. Kopf, Daniel M. Green, John A. Rogers, Wenling Kao, Christine Huselton, John F. Mehlmann, Joseph T. Lundquist, Lloyd M. Garrick, James W. Jetter
Publikováno v:
Bioorganic & Medicinal Chemistry. 16:6617-6640
Antagonism of the gonadotropin releasing hormone (GnRH) receptor has shown positive clinical results in numerous reproductive tissue disorders such as endometriosis, prostate cancer and others. Traditional therapy has been limited to peptide agonists